Pharmaceutically acceptable salt and crystal form of 1,4-dihydro-1,6-naphthyridine amide compound and preparation method therefor
AssigneeJiangsu Hengrui Pharmaceuticals Co., Ltd.
InventorsJiaqi YAO, Junran YANG, Zhenxing DU, Jie WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a pharmaceutically acceptable salt (formula 1) and a crystal form of a 1,4-dihydro-1,6-naphthyridine amide compound, and a preparation method therefor. Specifically, provided in the present disclosure are a pharmaceutically acceptable salt and crystal form of (S)-4-(3-acetyl-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-4-yl)-3-(methoxy-d3)benzonitrile, and a preparation method therefor. The corresponding crystal form has good stability and can be better used for clinical treatment.
Claims22
A pharmaceutically acceptable salt of the compound of formula 1, (S)-4-(3-acetyl-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-4-yl)-3-(methoxy-d3)benzonitrile, wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, sulfate, phosphate, hydrobromide, mesylate, p-toluenesulfonate, tartrate, maleate, citrate, and malate,
7-15. (canceled)
A crystal form A of the compound of formula 1, wherein an X-ray powder diffraction pattern expressed in terms of 2θ angles, which are diffraction angles, of the crystal form has characteristic peaks at 8.459, 13.964, 18.987, 22.914, and 25.530;
- wherein each 2θ angles have a margin of error of ±0.20.
(canceled)
Dependencies are inferred from the claim text.